Was The Delay Preventable?
If a physician dismissed your headaches, attributed your seizures to stress, or sent you home from the emergency department without imaging — and a brain tumor was later found — you deserve to know whether that delay was preventable.
Contact Us for a Free, Confidential Consultation
Article written by Gregory Unatin, Esq. Greg is a managing partner in the law firm of Lupetin & Unatin, a medical malpractice law firm located in Pittsburgh and serving Western Pennsylvania.
We have dedicated our practice to medical malpractice cases, and have represented clients in cases of delayed or missed diagnosis of cancer.
Brain cancer does not announce itself with unmistakable signs; its early symptoms are common, easy to explain away as chronic, non-life-threatening issues. The symptoms are frequently misattributed to tension headaches, anxiety, or other conditions that physicians see hundreds of times a week. But just because most patients have minor headaches does not excuse a doctor’s failure to rule out dangerous ones. At Lupetin & Unatin, we investigate cases in which that failure — to order the right imaging, to make the right referral, to take the right symptoms seriously — allowed a brain tumor to grow past the point where the patient had a fighting chance.
What Is Brain Cancer, and Why Does Early Diagnosis Matter?
Brain cancer is not a single disease. It encompasses a range of malignant tumors that originate in, or spread to, the brain and surrounding structures of the central nervous system. Primary brain tumors begin in the brain itself — arising from glial cells, neurons, the meninges, or other supporting structures. Metastatic brain tumors, by contrast, originate elsewhere in the body (most commonly in the lungs, breast, colon, kidney, or skin) and travel to the brain through the bloodstream. Both categories of brain tumors can be devastating for a patient and their loved ones, and both present diagnostic challenges that trained physicians are obligated to confront.
The most common and most lethal primary brain tumor in adults is glioblastoma multiforme (GBM), classified as a WHO Grade IV astrocytoma. Lower-grade gliomas — WHO Grade 2 and 3 — are slower-growing tumors that carry meaningfully better prognoses when caught before they transform into higher-grade malignancies. Without diagnosis and treatment, a WHO Grade 2 glioma will, in most patients, progress to Grade 3 or 4 over time. Other primary tumor types include meningiomas (arising from the meninges surrounding the brain), ependymomas, medulloblastomas (most common in children), and oligodendrogliomas.
Critically, the standard of care for classifying brain tumors now requires more than just a microscopic examination of tumor cells. Under the current WHO Classification of CNS Tumours and NCCN Guidelines, physicians must provide an ‘Integrated Diagnosis’ that combines traditional histology with molecular profiling. For example, a tumor is now classified as a Glioblastoma (Grade 4) only if it is IDH-wildtype. If the same-looking tumor possesses an IDH mutation, it is classified as an Astrocytoma, IDH-mutant.
A failure by a pathologist or oncologist to order or interpret analyses of these molecular markers (such as IDH status, 1p/19q codeletion, and MGMT methylation) can lead to a fundamental misdiagnosis of the tumor’s aggressiveness and appropriate treatment path.
GBM vs. Lower-Grade Gliomas: Why the Distinction Matters for Diagnosis and Urgency
The difference between a GBM and a low-grade glioma is not simply a matter of degree — it is a difference in prognosis, treatment approach, and the clinical calculus of what a delay costs the patient. A physician, radiologist, or pathologist who fails to distinguish between these tumor types — or who fails to evaluate a patient with a suspected low-grade lesion on the assumption that it ‘can wait’ — may cause irreversible harm. Understanding that distinction is essential both to the medical standard of care and to the legal analysis of any delay case.
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. It grows rapidly, is almost always fatal, and carries a 5-year relative survival rate of approximately 6.8% according to SEER data published by the National Brain Tumor Society. Comparing the 6.8% 5-year survival rate to a 70% overall 5-year survival rate currently reported across all cancers underscores the threat posed by GBM. Even within the GBM category, delay matters: a smaller tumor at diagnosis may allow for greater extent of surgical resection, and gross total resection is associated with improved outcomes. For example, a delay in diagnosis which allows a tumor to grow from an operable size and location to one infiltrating the corpus callosum or brainstem may shift from surgically resectable to unresectable — a direct, compensable consequence of the delay.
Lower-grade gliomas present an entirely different calculus — and one where the consequences of delay are, in many cases, more clearly compensable. A WHO Grade 2 glioma in a young adult may remain stable for years or may progress slowly. The window for diagnosis and intervention — surgical resection, radiation, surveillance — can be years long. But that window is not infinite. When a physician repeatedly evaluates a young patient with new-onset seizures or progressive headaches and fails to order an MRI that would have revealed a Grade 2 lesion, and that lesion subsequently transforms to Grade 4 during the period of delay, the harm is precise: a patient who had a Grade 2 glioma is now facing a GBM, and they are facing it because no one looked for the tumor when looking was the right thing to do.
For anaplastic gliomas (Grade 3), the urgency sits between the two extremes described above. These tumors are aggressive, but patients whose Grade 3 tumors are identified before they accumulate additional molecular alterations and progress to Grade 4 have meaningfully better outcomes. Every month of delay in diagnosing a Grade 3 glioma is a month in which the tumor may cross a molecular threshold from which there is no return.
The practical consequence for malpractice investigation is this: in a GBM case, the causation argument often focuses on what surgical options were lost during the delay. In a low-grade glioma case, the causation of harm issues involves the tumor’s transformation to a higher grade — or the patient’s loss of years of functional, seizure-controlled life that earlier intervention would have preserved. In a Grade 3 case, it addresses the narrowing window before the tumor reached the threshold of GBM-level lethality. Each analysis requires different expert testimony, different survival data, and a different reconstruction of what ‘timely diagnosis’ would have meant in that specific patient’s course.
| WHO Grade / Tumor Type | Median Survival / 5-Yr Rate | Why Delay Is Harmful — Legal and Clinical Significance |
|---|---|---|
| Grade I (e.g., pilocytic Grade I (e.g., pilocytic astrocytoma) | ~95% (5-yr) | Highly curable with complete resection. Delay allows growth into eloquent cortex, reducing likelihood of gross total resection. Most common in children. |
| Grade 2 (low-grade glioma) | ~50–70% (5-yr) | May appear stable for years — but untreated, most transform to Grade III or IV. Delay is the proximate cause of grade transformation. Loss of years of functional life is compensable harm. |
| Grade 3 (anaplastic glioma) | ~25–35% (5-yr) | Median survival 2–3 years. Rapid progression to GBM if untreated. Delay closes the window before the tumor accumulates GBM-level molecular alterations. |
| Grade 4 (GBM) | ~5–10% (5-yr); median ~14–16 months | Most aggressive. Delay reduces extent of resection, shortens time on active treatment, and accelerates neurological decline. Even in fatal cases, lost functional months are compensable. |
| Malignant meningioma | ~55–65% (5-yr) | Often misidentified as benign on imaging. Delayed recognition of malignant features allows brain invasion and reduces resectability. |
| Metastatic brain tumor | Varies by primary cancer type | Early detection allows stereotactic radiosurgery (SRS) targeting of individual lesions before spread to multiple sites. Delay from the primary cancer team failing to image the brain is a distinct mechanism of negligence. |
Sources: National Brain Tumor Society, citing NCI SEER data (GBM 5-year relative survival ~6.8%); Central Brain Tumor Registry of the United States (CBTRUS) 2025 Statistical Report — Primary Brain and Other CNS Tumors Diagnosed in the United States 2018–2022 (Price M et al., Neuro Oncol. 2025; doi:10.1093/neuonc/noaf194); American Cancer Society Cancer Statistics 2026 (overall all-cancer 5-year survival milestone of 70%); Stupp R et al., NEJM 2005 (GBM standard-of-care treatment; median 14.6 months in treated trial population); WHO Classification of CNS Tumours, 5th Edition (WHO CNS5), 2021 — Arabic numeral grading (Grade 1–4). Note: Current 2026 standards require molecular confirmation (Integrated Diagnosis) for definitive grading of all gliomas.
Because brain tumors grow within the fixed, enclosed space of the skull, they cause harm through two mechanisms: direct destruction of brain tissue as the tumor infiltrates, and compression of surrounding structures as the mass expands. Neither process waits. The months that a misdiagnosis or delayed referral costs a patient are not meaningless— they can be the difference between a tumor that is surgically resectable and one that is not, or between a Grade II glioma and a Grade IV death sentence.
Who Is Most at Risk? Risk Factors and the Duty of Heightened Vigilance
Brain cancer does not discriminate sharply by lifestyle in the way that lung or colorectal cancer does, which makes risk-factor-based screening less straightforward — and makes detection of symptoms even more critical. Still, there are established risk factors for brain cancer, and when a patient presents with relevant symptoms in the context of risk factors, the physician has an obligation to investigate.
Ionizing radiation exposure is the only well-established environmental risk factor for primary brain tumors. Patients who received cranial radiation therapy for prior malignancies — particularly childhood cancers treated decades ago — carry an elevated lifetime risk of secondary brain tumors. This history is often in the medical record. A physician who reviews a patient’s cancer treatment history and sees prior cranial radiation must apply a lower threshold for neuroimaging when that patient presents with headaches or neurological symptoms.
Certain hereditary syndromes are associated with significantly elevated brain tumor risk. Neurofibromatosis type 1 (NF1) and type 2 (NF2), Li-Fraumeni syndrome (TP53 mutations), Turcot syndrome, and Cowden syndrome all carry elevated rates of specific brain tumor types. When a patient discloses a family history consistent with one of these syndromes, or when they have an established diagnosis, the standard of care requires neurological vigilance. Failure to account for hereditary risk in the evaluation of neurological symptoms is negligence.
Other recognized risk factors include male sex (men develop gliomas at approximately 1.6 times the rate of women); age (the median age of GBM diagnosis is approximately 64, though gliomas at all grades affect patients from childhood through late adulthood); and, for metastatic brain tumors, any history of cancer in a different location of the body — particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. A patient with a known history of any of these cancers who develops new or worsening neurological symptoms requires brain imaging promptly and without exception.
The practical implication for malpractice investigation is this: when a patient has one or more of these risk factors and presents with symptoms consistent with a brain tumor — and their physician dismisses those symptoms without imaging — the case for negligence is stronger, not weaker. The physician had more reason to suspect a serious cause. Failure to act on that heightened duty is not a lesser deviation from the standard of care; it is a greater one.
Clinical Red Flags: Symptoms Physicians Are Required to Investigate
The symptoms of brain cancer are produced by two processes: local damage to the specific area of brain tissue where the tumor is growing, and the generalized effects of increased intracranial pressure as the mass expands. A competent physician performing a neurological history and examination should ask questions that identify both local and generalized symptoms — and should understand what those symptoms localize to anatomically. The four categories of red-flag symptoms below are not subtle or ambiguous. Each has a well-documented relationship to a problem within the structure of the brain. Each demands a defined medical response. And in each category, attributing the symptom to a psychiatric cause — stress, anxiety, depression — without first obtaining neuroimaging may quality as malpractice.
New-Onset or Progressive Headaches
Not every headache is a brain tumor, and no physician is expected to image the brain of every patient who presents with a headache. The standard of care does not require that. What it requires is that a physician who encounters certain headache characteristics recognize them as red flags and act accordingly. Physicians should not attribute red-flag features to stress, tension, or psychiatric distress before structural issues in the brain have been excluded.
The features that require imaging are well-established in the published literature and in the clinical policies of ACEP and the American Headache Society: a headache that is new in a patient over 50; a headache that is progressively worsening over weeks or months; a headache that is worst upon waking or that wakes the patient from sleep (a pattern reflecting increased intracranial pressure, which peaks with recumbency); a headache provoked by Valsalva maneuvers — bending over, coughing, or straining — because these activities transiently increase intracranial pressure; a headache accompanied by any focal neurological finding; and a headache in an immunocompromised patient or one with a history of cancer. These are not obscure criteria available only to specialists. They are taught in medical school and are reflected in peer-reviewed clinical guidance documents that primary care physicians, emergency physicians, and neurologists are expected to know.
A physician who sees a patient three, four, or five times for progressively worsening morning headaches and prescribes ibuprofen and stress management without ordering a single imaging study has not applied these criteria. The defense argument — that the headaches ‘could have been tension headaches’ — does not address the legal question, which is not whether tension headaches were possible, but whether the physician met the standard of care for a patient whose headache had features requiring exclusion of a structural cause. Those are different questions, and juries who are walked through them carefully understand the difference.
New-Onset Seizures in Adults
A first unprovoked seizure in an adult is a neurological emergency. The American Academy of Neurology (AAN) and American Epilepsy Society (AES) evidence-based guideline on management of an unprovoked first seizure in adults — published in Neurology in 2015 (Krumholz A et al., Neurology 84:1705-1713) and formally reaffirmed by the AAN on February 10, 2024 — establishes that CT or MRI brain imaging should be routinely considered for every adult presenting with a first unprovoked seizure (Level B recommendation). MRI is the preferred modality in the non-acute setting because of its substantially superior sensitivity for the structural abnormalities — including tumors — that cause seizures. This is not a new or contested standard: it has been the published Level B recommendation of the AAN for over a decade, reaffirmed in 2024, and forms the baseline against which emergency and neurology physicians are evaluated in delay cases. There is no clinical justification for attributing a first adult seizure to stress, poor sleep, or anxiety and discharging the patient without brain imaging.
Yet this is precisely what happens in a meaningful number of cases that eventually present to malpractice attorneys. A patient has a witnessed seizure, presents to an emergency department, receives blood tests and a non-contrast CT, and is discharged with a new prescription for levetiracetam and a follow-up appointment with a neurologist scheduled weeks away. When the neurologist finally orders an MRI — because the AAN guideline says to — the MRI reveals a mass. The non-contrast CT was negative not because no tumor was there, but because non-contrast CT is poorly sensitive for the structural lesions most commonly associated with first seizures. The AAN guideline recommends MRI for this reason. Ordering a CT instead of an MRI in this context is not simply a clinical preference — it is a deviation from a published, consensus-based standard of care.
The same principle applies when a physician attributes a new adult seizure to psychiatric causes. Patients with anxiety, PTSD, or other psychiatric diagnoses are disproportionately at risk of having their seizures attributed to ‘pseudoseizures’ or ‘functional neurological disorder’ without adequate structural imaging. While psychogenic non-epileptic seizures (PNES) do occur, the standard of care requires that structural causes — including brain tumors — be excluded before a PNES diagnosis is made. Attributing a seizure to psychiatric causes and withholding imaging is not an exercise of clinical judgment; it is a failure to apply the diagnostic standard.
Focal Neurological Deficits
New weakness in one arm or leg, difficulty finding words (expressive aphasia), visual field deficits, facial asymmetry, or loss of coordination that cannot be attributed to a known peripheral nerve, musculoskeletal, or metabolic cause all require neuroimaging. These are localizing signs — they point to a specific region of the brain or central nervous system where something is wrong. A physician who attributes new weakness in a single arm to a rotator cuff injury, or who attributes new word-finding difficulty to fatigue, depression, or normal aging, and does not order neuroimaging, has committed the fundamental error of anchoring on a benign diagnosis without excluding a dangerous condition of the central nervous system.
Doctors must not attribute focal neurological deficits to psychiatric or functional causes without brain imaging. Neuropsychiatric conditions like conversion disorder and functional neurological symptom disorder are recognized diagnoses, but they are diagnoses of exclusion — meaning that structural causes, including brain tumors, must be excluded before the patient is formally diagnosed. A physician who labels new hemiparesis as ‘functional’ without an MRI of the brain has not completed the evaluation that the label requires. If that hemiparesis is later shown to have been caused by a tumor that was growing at the time of the misdiagnosis, the failure to image is the proximate cause of the delayed diagnosis and all the harm that followed.
Personality and Cognitive Changes
Tumors in the frontal and temporal lobes of the brain frequently present not with headache or focal motor weakness, but with changes in personality, judgment, memory, and executive function. A patient whose family reports that they have become uncharacteristically impulsive, apathetic, or disinhibited — or whose own reports describe progressive memory failure, difficulty with planning and organization, or word-finding trouble — has symptoms that localize to the frontal or temporal lobes. These presentations can be mistaken for depression, burnout, early dementia, or anxiety. The mistake is not always negligent. But it becomes negligent when the physician attributes these symptoms to psychiatric illness without performing an adequate neurological examination, without screening for cognitive impairment using a validated tool, and without imaging to exclude a structural cause within the brain.
The reason this matters legally is that frontal lobe tumors, in particular, can reach a very large size before the patient seeks medical care — because personality and behavioral changes are often attributed to life circumstances rather than neurological disease, and because the patient themselves may lack insight into their own deterioration. When a brain tumor is finally diagnosed after months of psychiatric treatment, the imaging often reveals a mass that has been growing throughout the period of misdiagnosis. The question for the jury is not whether depression could have explained the symptoms — it is whether a physician exercising reasonable care would have obtained imaging before committing to a psychiatric diagnosis in a patient without prior psychiatric history.
Cognitive changes must not be attributed to stress or psychiatric causes without neuroimaging when there is no prior psychiatric history, when the onset is acute or subacute, when there are any accompanying focal neurological signs, or when the patient has any of the risk factors described in the preceding section. These are not obscure or undefined rules — they are standards derived from the published neurological literature and practiced by neurology providers in Pittsburgh and throughout Pennsylvania.
The Standard of Care: Clinical Guidelines Governing Brain Tumor Diagnosis
Unlike breast or colorectal cancer, there is no population-wide screening program for brain tumors. No guideline organization recommends routine brain MRI in asymptomatic individuals. This makes the standard of care for brain tumor diagnosis entirely symptom-driven — which means the physician’s response to what the patient reports, and what the physician finds on examination, is everything.
American Academy of Neurology (AAN) — Evaluation of the First Seizure
The AAN and American Epilepsy Society evidence-based guideline on management of an unprovoked first seizure in adults (Krumholz A et al., Neurology 84:1705-1713, 2015; reaffirmed by the AAN February 10, 2024) establishes that neuroimaging — CT or MRI — should be routinely considered in adults presenting with a first unprovoked seizure, with MRI preferred over CT in the non-acute setting because of its superior sensitivity for detecting the structural lesions, including gliomas and other brain masses, that cause seizures. This is a Level B recommendation that has been in place for over a decade and was formally reaffirmed in 2024. A physician who orders no imaging, or who orders only a non-contrast CT in a non-emergency setting and treats a normal result as definitively excluding a brain mass, has deviated from this long-standing published standard. From a legal standpoint, this deviation is particularly difficult to defend because the guideline’s age and reaffirmation demonstrate that the standard was not obscure or emerging — it was well-established, widely-taught, and formally reconfirmed.
ACEP and American Headache Society — Headache Evaluation
ACEP’s Clinical Policy on the evaluation and management of adult patients presenting to the emergency department with acute headache (Ann Emerg Med. 2019;74(4):e41–e74; approved by the ACEP Board of Directors June 26, 2019; endorsed by the Emergency Nurses Association July 31, 2019) provides the current published standard for risk-stratifying headache patients and determining when emergent neuroimaging is indicated. This is ACEP’s most current headache clinical policy; no superseding update has been issued. While the policy focuses on acute emergency presentations, particularly ruling out subarachnoid hemorrhage, it identifies validated risk-stratification criteria — including the Ottawa SAH Rule — that require imaging in high-risk presentations. For progressive headaches presenting over multiple outpatient visits, or headaches accompanied by focal neurological findings, the ACR Appropriateness Criteria — not the ACEP ED policy — are the primary standard-of-care reference: MRI of the brain with and without gadolinium contrast is rated ‘usually appropriate’ by the ACR for chronic progressive headache, new neurological deficit, and headache in immunocompromised patients. A physician who encounters these red-flag features and fails to order MRI — instead attributing symptoms to tension headache without imaging — has not met either the ACEP or ACR standard.
NCCN — CNS Cancer Guidelines
The NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers establish the complete diagnostic workup required once a brain mass is identified: MRI of the brain with and without gadolinium contrast, evaluation for systemic primary cancer, and tissue diagnosis — typically through stereotactic biopsy or surgical resection — with a pathology report that includes not only WHO grade and histological type but also the molecular markers (IDH mutation status, MGMT methylation, 1p/19q co-deletion) that have direct implications for prognosis and treatment. A pathologist who issues a brain tumor diagnosis without these markers has provided an incomplete and potentially substandard report.
ACR Appropriateness Criteria — Headache
The American College of Radiology Appropriateness Criteria for headache rate MRI of the head without and with contrast as ‘usually appropriate’ for chronic progressive headache, new neurological deficit, and headache in an immunocompromised patient. When a physician orders a CT instead of an MRI for a patient with a progressive, red-flag headache, and the CT is read as normal while a tumor is present that MRI would have identified, the imaging choice itself may constitute a deviation from the ACR standard.
MRI vs. CT: Why the Choice of Imaging Modality Is a Standard-of-Care Decision
One of the most important — and most frequently litigated — questions in brain cancer delay cases is not whether imaging was ordered, but whether the right imaging was ordered. A physician who orders a CT scan in response to symptoms that require an MRI has not met the standard of care, even if the CT was performed promptly and accurately read by a qualified radiologist. CT and MRI are not interchangeable modalities for evaluating the brain. They have different capabilities, different limitations, and different clinical indications — and when a physician chooses CT in a situation where MRI is indicated, they may be choosing a test that cannot detect the very thing they should be looking for.
What CT Scans Can and Cannot Do
A non-contrast CT of the head is the appropriate first-line imaging study in the emergency setting for a small number of specific indications: acute stroke (to exclude hemorrhage before thrombolytic treatment), acute head trauma, suspected intracranial hemorrhage, and evaluation of hydrocephalus. It is fast, widely available, and adequate for these high-acuity, hemorrhagic presentations. For these purposes, CT is the right choice.
For detecting brain tumors — particularly small tumors, low-grade gliomas, cortically based lesions, tumors in the posterior fossa (cerebellum and brainstem), and lesions that do not cause significant mass effect — non-contrast CT is substantially less sensitive than MRI. A non-contrast CT may appear completely normal in a patient who has a brain tumor that would be immediately visible on MRI with gadolinium contrast. The reason is structural: CT uses ionizing radiation to generate images based on tissue density differences. Tumors that are isodense to normal brain tissue — meaning they have a similar density — will not be visible on CT. Low-grade gliomas, in particular, are frequently isodense on CT and may be invisible until they are large enough to cause distortion of surrounding structures.
A CT with contrast adds iodinated contrast material, which can enhance some tumors — particularly GBM, which has disruption of the blood-brain barrier and will often show enhancement on CT. However, CT contrast enhancement is still significantly less sensitive than MRI with gadolinium for detecting small enhancing lesions, leptomeningeal disease, and posterior fossa tumors. And CT with contrast carries the added burden of contrast nephropathy risk, making non-contrast CT the routine emergency CT of choice — which means the vast majority of emergency head CTs are done without contrast, and their sensitivity for brain tumors is limited.
What MRI Provides That CT Cannot
MRI is the diagnostic gold standard for the evaluation of the brain in any patient with a non-emergency neurological presentation. It offers substantially superior soft-tissue contrast resolution compared to CT, allowing visualization of tumors that are imperceptible on CT. It can detect tumors in the posterior fossa — the region containing the cerebellum and brainstem — without the beam-hardening artifact that degrades CT images of this area. It visualizes the temporal lobes, which CT images poorly due to adjacent bony structures.
Gadolinium contrast MRI adds a further dimension that is essential in brain tumor evaluation. Gadolinium is a paramagnetic contrast agent that highlights areas where the blood-brain barrier has been disrupted — a characteristic feature of high-grade gliomas, brain metastases, and many other intracranial malignancies. A ring-enhancing lesion on gadolinium MRI — a characteristic pattern of peripheral enhancement with central necrosis — is highly suspicious for GBM or brain metastasis, and its presence mandates urgent neurosurgical consultation. This pattern can be missed entirely on a non-contrast CT, or mischaracterized as artifact on a CT with inadequate resolution.
MRI also supports advanced imaging sequences that are standard in the evaluation of a known or suspected brain mass. Fluid-attenuated inversion recovery (FLAIR) imaging highlights edema surrounding a tumor, allowing assessment of the extent of surrounding brain involvement. Diffusion-weighted imaging (DWI) helps characterize the type of lesion. MR spectroscopy can provide metabolic information that distinguishes between tumor recurrence and treatment-related changes. Perfusion MRI helps differentiate high-grade from low-grade tumors. These sequences are not available on CT, and for patients whose brain tumors are discovered — or suspected — in a non-emergency setting, they represent the complete standard-of-care evaluation.
When the Choice of CT Over MRI Constitutes Negligence
The clinical scenarios in which CT is an inadequate substitute for MRI are well-defined by the published guidelines and the medical literature:
- First unprovoked adult seizure in a non-acute setting: The AAN/AES guideline (Neurology 84:1705-1713, 2015; reaffirmed February 10, 2024) recommends brain imaging be routinely considered, with MRI as the preferred modality over CT. This Level B recommendation has been in place for over a decade. A physician who orders only a non-contrast CT for a first adult seizure and discharges the patient on the strength of a normal CT has not met the published standard. The legal significance: this is not a novel or emerging guideline that a physician might reasonably have been unaware of. It was published in 2015 and formally reaffirmed in 2024. Its age and reaffirmation make it unusually strong ground for establishing breach.
- Progressive headache with neurological findings: When a patient presents with a headache that meets imaging criteria under ACEP or American Headache Society guidelines and also has any focal neurological finding — even subtle — MRI with and without gadolinium is the appropriate modality, not CT. The ACR Appropriateness Criteria make this explicit.
- Posterior fossa symptoms: A patient with progressive gait ataxia, diplopia, or nausea and vomiting without a GI cause may have a posterior fossa tumor. CT of the posterior fossa is significantly degraded by bony artifact. MRI is the only adequate imaging modality for evaluation of this region.
- Suspected low-grade glioma in a young adult: Low-grade gliomas are frequently invisible on CT. A young adult with new-onset seizures, progressive headache, or cognitive changes has a meaningful probability of a low-grade glioma. Ordering only a CT in this clinical context does not meet the standard of care.
- Follow-up of a previously identified lesion: Once a brain lesion has been identified on any imaging modality, all subsequent evaluation must be performed with MRI unless there is a contraindication (such as a non-MRI-compatible implant). Using repeat CT to monitor a previously identified lesion is below the standard of care.
In each of these scenarios, the legal consequence of ordering CT instead of MRI is that the physician has chosen a test that could — and in many delayed-diagnosis cases, did — fail to identify the tumor that was causing the patient’s symptoms. A normal CT result does not provide the clinical assurance that a normal MRI would provide. When a physician discharges or reassures a patient based on a normal CT in a situation where MRI was indicated, the physician has violated the published standard of care. If the tumor is subsequently found on MRI months or years later at a more advanced stage, that substitution is a direct cause of the delay.
The Physician’s Obligation to Select the Right Test — and to Explain Its Limitations
The standard of care requires not only that physicians order appropriate imaging, but that they understand the limitations of the imaging they order. A physician who orders a non-contrast CT, receives a normal result, and interprets that result as excluding a brain tumor has made a diagnostic error — not because the CT was read incorrectly, but because the physician did not understand that a normal non-contrast CT does not exclude a brain tumor. This misinterpretation of a test’s diagnostic limitations is itself a form of negligence, distinct from the initial decision about which test to order.
The same principle applies to the radiologist. A radiologist who reads a normal non-contrast CT and issues a report without noting the limitations of CT compared to MRI for the clinical question of brain tumor — when the clinical indication on the requisition form includes symptoms suggestive of a mass lesion — may also be below the standard of care. The ACR guidelines on reporting and the general standards of neuroradiology practice require that radiologists flag the limitations of their studies when those limitations are clinically relevant. A radiologist who reads a CT as normal and does not note that MRI would be needed to exclude a brain mass in a patient with progressive neurological symptoms has not completed their professional obligation.
| Clinical Situation | Appropriate Imaging | What CT Alone May Miss |
|---|---|---|
| First unprovoked adult seizure | MRI brain with and without gadolinium contrast (AAN guideline) | Small cortical or subcortical tumor; isodense low-grade glioma; posterior fossa lesion; leptomeningeal disease |
| Progressive or red-flag headache with focal neuro findings | MRI brain with and without gadolinium contrast (ACR Appropriateness Criteria) | Low-grade glioma; small cortically based metastasis; early mass effect without hemorrhage |
| New personality or cognitive change without prior psychiatric history | MRI brain with gadolinium (neurology standard of care) | Frontal lobe glioma; temporal lobe tumor; corpus callosum involvement; non-enhancing infiltrating glioma |
| Posterior fossa symptoms (ataxia, diplopia, vomiting) | MRI brain with gadolinium, dedicated posterior fossa sequences | Cerebellar glioma; brainstem glioma; ependymoma; metastasis — all degraded on CT by bony artifact |
| Follow-up of known brain lesion | MRI with gadolinium at intervals per NCCN / neuro-oncology guidance | Any progression in tumor size, grade transformation, or development of enhancement not visible on CT |
| Known systemic cancer with new neurological symptoms | MRI brain with gadolinium — urgent, same day if possible | Small metastases (< 1 cm); leptomeningeal metastasis; multiple lesions; dural metastasis |
Common Mechanisms of Negligent Delay: How Brain Cancer Is Missed
The Progressive Headache Attributed to Tension or Stress
A 52-year-old man visits his primary care physician three times over five months reporting worsening morning headaches that are unlike any he has experienced before. He describes them as pressure-like, worst when he first wakes up, and sometimes accompanied by nausea. Each time, his physician diagnoses tension headache, prescribes ibuprofen, and advises stress management. No neurological examination is documented. No imaging is ordered. At his fourth visit, his wife reports two recent episodes of confusion. An emergency MRI reveals a large right frontal GBM that has already crossed the corpus callosum — a finding that removes it from the category of lesions amenable to gross total resection. The failure to recognize the morning-predominant, progressive character of the headaches as a red flag for elevated intracranial pressure — and the three-visit pattern of non-investigation — are the core negligence. A CT ordered at any of the prior visits might also have missed this tumor had it not yet developed significant mass effect; an MRI with gadolinium would not have.
The Adult Seizure Discharged on CT Alone
A 44-year-old woman with no prior seizure history is brought to a Pittsburgh-area emergency department after a witnessed generalized tonic-clonic seizure at work. Laboratory studies are normal. A non-contrast CT of the head is performed and read as normal. The emergency physician attributes the seizure to dehydration, prescribes levetiracetam, and discharges her with neurology follow-up in four weeks. Ten days later, she has a second seizure. The neurologist orders an MRI with gadolinium, which reveals a ring-enhancing mass in the left temporal lobe. The non-contrast CT missed the lesion entirely. The AAN/AES guideline on first adult seizure management (Neurology 84:1705-1713, 2015; reaffirmed February 10, 2024) identifies brain imaging as essential and MRI as the preferred modality in the non-emergency setting — a Level B recommendation in place for over a decade. Ordering only a non-contrast CT and treating a normal result as definitively excluding a brain mass is a deviation from this long-standing published standard. The guideline’s age makes this breach exceptionally difficult for the defense to minimize.
The Incidental Finding Never Communicated
A 61-year-old man undergoes a CT scan of his sinuses for chronic sinusitis. At the margin of the imaging field, the radiologist identifies a 1.5 cm lesion in the left temporal lobe and describes it as an ‘incidental finding of uncertain significance,’ recommending dedicated brain MRI for further evaluation. The ENT surgeon who ordered the sinus CT reviews the sinus findings but does not read to the end of the report. The patient is never told about the lesion, and no MRI is ordered. Fourteen months later, he presents to a neurologist for progressive word-finding difficulty. MRI reveals a high-grade glioma in the same location. Both the radiologist — for failing to communicate a critical finding directly to the ordering physician — and the ordering physician — for failing to read and act on the recommendation — may bear legal responsibility. The temporal lobe CT finding was present. The MRI that would have characterized it was never ordered. The standard of care for both parties was breached.
The Personality Change Attributed to Depression
A 58-year-old woman is brought to her family physician by her husband, who describes his wife as uncharacteristically impulsive, apathetic, and forgetful over the past four months. She occasionally struggles to find words in conversation. The physician diagnoses major depressive disorder and prescribes an SSRI. No neurological examination is documented. No cognitive screening is performed. No imaging is ordered. Over six months of psychiatric treatment, her symptoms worsen. A psychiatrist who evaluates her identifies expressive language deficits inconsistent with depression. MRI reveals a large left frontal-temporal glioma with significant surrounding edema. The failure to consider a structural brain lesion in the differential diagnosis of a new-onset behavioral and cognitive change in a middle-aged adult without prior psychiatric history — and to perform, document, and act on an adequate neurological examination — is the mechanism of negligence. Personality change and cognitive decline must not be attributed to psychiatric causes without imaging when they arise acutely or subacutely in a patient without established psychiatric illness.
The Radiology Misread: Tumor Labeled a Benign Variant
A 47-year-old woman undergoes a brain MRI ordered by her neurologist for persistent headaches. The MRI reveals a small enhancing lesion in the right parietal lobe. The radiologist describes it as a ‘likely developmental venous anomaly’ and does not recommend follow-up. The neurologist, relying on this characterization, reassures the patient that her imaging is essentially normal. Sixteen months later, after worsening symptoms prompt repeat MRI, the lesion has grown substantially and now shows imaging features consistent with high-grade glioma. The radiologist’s initial characterization — labeling an enhancing lesion as likely benign without recommending short-interval follow-up or specialist review — is the core breach. NCCN guidelines and neuroradiology standards require that any enhancing brain mass be characterized with specificity and that indeterminate lesions be recommended for follow-up imaging or neurosurgical consultation. A ‘probably benign’ label without a follow-up recommendation is clinically and legally inadequate when the consequences of a missed brain tumor are what they are.
When Delay Has a Face: A Real Brain Tumor Misdiagnosis Case Handled by Lupetin & Unatin
The following is a summary of an actual delayed brain tumor diagnosis case litigated by the attorneys of Lupetin & Unatin in a Western Pennsylvania county court. Identifying details have been changed to protect the client’s privacy. The case illustrates, in human terms, how the failures described throughout this article occur in the lives of real patients.
Megan was a teenager from western Pennsylvania when her symptoms began. She was a National Merit Scholar, a member of the National Honor Society, and a student leader in her school community — a young woman, by every measure, with an extraordinary future in front of her.
For years before her diagnosis, Megan was experiencing a constellation of symptoms that her physicians failed to connect: recurring headaches, visual disturbances including light flashes and floaters, nausea, tinnitus (ringing and swooshing in one ear), and progressive hearing loss. Each symptom, considered in isolation, might have a benign explanation. Considered together — and traced over time — they were the signature of a growing brain tumor pressing against the structures of her skull.
The Family Practice Physician
Megan had been a patient of her family medicine physician since childhood. In 2012, one of his partners saw Megan for complaints of ear pain and a swooshing noise in the right ear and documented diagnoses of tinnitus and hearing loss. Megan was referred for audiology testing and an ENT consultation. The ENT specialist identified a mild low-frequency conductive hearing loss and specifically recommended repeat audiologic testing within two months — noting that hearing loss from an intracranial process (sensorineural hearing loss) had not been ruled out. That follow-up testing never happened.
When the family practice physician saw Megan for a wellness visit in 2014, her hearing examination showed no response at 500Hz and 1000Hz frequencies — objective evidence of significant hearing loss. He did not perform a comprehensive review of Megan’s ongoing symptoms, did not connect the hearing findings to the previous tinnitus workup, did not follow up on the ENT’s recommendations, and did not refer Megan for neurological evaluation. The visit was documented as a routine health maintenance exam.
At a visit approximately a year later, the family practice physician again saw Megan. The chart attributed her headaches to stress and anxiety. He was also in a position to know about an emergency department visit Megan had made only three months earlier, when she presented to a local hospital with a headache and neck and back tightness so severe it made walking difficult. That prior ER visit and its implications were not addressed. Megan was sent home without neurological referral.
The Optometrist
Megan’s optometrist saw her repeatedly over the same period. At Megan’s first visit, the optometrist performed visual field testing because she recognized that Megan’s complaints of floaters, light flashes, headaches, and nausea could be caused by a brain lesion. That initial test was normal.
At a follow-up visit approximately two years later, visual field testing now showed defects — three points missed in one quadrant of one eye, four in another quadrant of the other. The optometrist found the results unreliable and chose not to repeat the test that day or at any subsequent visit, instead substituting a grosser, less sensitive form of visual assessment. Plaintiff’s expert in optometry would have testified that the optometrist should have recognized the worsening pattern across the two tests as a sign of an intracranial process, and that any uncertainty about the reliability of the follow-up test obligated her to repeat it promptly.
Over the following three years, Megan continued to present at successive optometry visits reporting headaches one to two times per week, light flashes, and nausea. At none of these visits did the optometrist refer Megan to a neurologist. At the final visit before Megan’s tumor was discovered — less than ten months before her diagnosis — plaintiff’s experts would have testified that the optometrist, had she properly examined Megan’s retina and optic nerve, would have observed signs of increased intracranial pressure demanding immediate neurological referral. Instead, she prescribed new eyeglasses.
The Diagnosis
Megan was eventually admitted to a major academic medical center after losing consciousness. Imaging revealed a very large meningioma — a brain tumor that had been growing, undetected and untreated, for years. Surgery removed the tumor, leaving a small residual mass. Following surgery, Megan’s tinnitus, hearing loss, and headaches resolved. But the damage to her vision was permanent.
The Consequences
Megan is legally blind as a result of the delay in diagnosing and treating her brain tumor. A small area of central vision in one eye is essentially all that remains of her sight. She was forced to drop out of college. She developed a seizure disorder as a result of the untreated tumor, requiring ongoing neurological management. She has spent years learning to live with blindness — teaching herself Braille, earning eligibility for a guide dog, and undergoing training to use the dog to regain some measure of independence.
Plaintiff’s experts in family medicine, optometry, and neurosurgery were prepared to testify that the constellation of symptoms Megan presented — tinnitus, hearing loss, progressive headaches, and visual field changes — was precisely the pattern that should have triggered neurological evaluation years before her diagnosis. The family practice physician had at least two specific opportunities to elicit that constellation and refer Megan for imaging. The optometrist had five. Had either physician fulfilled their obligation, a meningioma identified earlier would very likely have been smaller, more surgically accessible, and far less damaging.
Instead, the tumor grew — and a young woman who had been a National Merit Scholar lost her sight.
A note on outcomes: This summary describes the factual circumstances of an actual case litigated by Lupetin & Unatin. Consistent with our firm’s standards, we do not disclose the terms or outcome of any individual case. If you or a family member experienced a similar delay in the diagnosis of a brain tumor or other serious condition, we encourage you to contact us for a confidential, no-cost review of your situation.
Standard of Care vs. Evidence of Negligence
The following table identifies the difference between appropriate clinical care and the documented failures that drive brain cancer malpractice claims. This framework is used by Lupetin & Unatin during case investigation.
| Clinical Area | Appropriate Standard of Care | Evidence of Negligence |
|---|---|---|
| Headache Evaluation | Red-flag features identified; neurological exam documented; MRI with gadolinium ordered when progressive, morning-predominant, exertional, or accompanied by focal findings. | Progressive headache attributed to tension without imaging. No neuro exam documented. Patient told to take OTC analgesics. Multiple visits without escalation. |
| Adult First Seizure Workup | MRI selected as the primary imaging modality in non-emergency neurological presentations, per ACR Appropriateness Criteria and AAN guidelines. Physician understands CT's limitations for detecting gliomas. | Non-contrast CT only, read as normal; patient discharged. Seizure attributed to stress, dehydration, or alcohol without brain MRI. No urgent neurology referral. |
| Choice of CT vs. MRI | MRI selected as the primary imaging modality in non-emergency neurological presentations, per ACR Appropriateness Criteria and AAN guidelines. Physician understands CT's limitations for detecting gliomas. | CT ordered instead of MRI for first seizure, progressive headache, or new cognitive change. Normal CT used to reassure patient without acknowledging CT's inability to exclude tumor. |
| Focal Neurological Deficits | New focal deficit triggers urgent MRI and neurological consultation. Structural cause excluded before attributing to functional, musculoskeletal, or psychiatric diagnosis. | Arm weakness attributed to rotator cuff. Word-finding difficulty attributed to aging or fatigue. Hemiparesis labeled 'functional' without imaging. Referral deferred. |
| Personality / Cognitive Changes | New behavioral or cognitive change triggers neurological exam, cognitive screening, and MRI before psychiatric diagnosis is made — particularly in patients without prior psychiatric history. | New behavioral symptoms treated with antidepressants without neurological exam or imaging. Diagnosis attributed to stress or depression in a patient without psychiatric history. |
| Imaging Interpretation | Radiologist uses NCCN and neuroradiology standards. Enhancing lesions characterized specifically. Indeterminate findings trigger follow-up recommendation. Critical findings communicated directly to ordering physician. | Enhancing mass labeled 'likely benign' without follow-up recommendation. Incidental finding not communicated. Normal CT falsely reassuring when MRI indicated. |
| Specialist Referral | Neurology or neurosurgery referral made urgently when imaging reveals mass lesion or when symptoms localize to CNS. Referral not delayed for convenience or administrative reasons. | Neurologist appointment scheduled weeks out with no urgency. Patient told imaging is 'probably nothing.' Mass identified; no referral made. Referral delayed pending repeat imaging never ordered. |
| Pathology Standards | WHO grade, histological type, and molecular markers (IDH, MGMT, 1p/19q) all reported per NCCN standards. Specimen reviewed by neuropathology when available. | Pathology report issued without molecular markers. Specimen processed without neuropathology expert review. Grade under-reported; treatment decisions made on incomplete data. |
What Makes a Brain Cancer Misdiagnosis Case Legally Viable in Pennsylvania?
To pursue a medical malpractice claim for delayed brain cancer diagnosis in Pennsylvania, four elements must be established: duty of care, breach of the standard of care, causation, and damages.
Duty of Care
A doctor-patient relationship establishes the duty. In brain cancer cases this commonly spans multiple providers — the primary care physician who evaluated the headaches, the emergency physician who saw the seizure, the radiologist who read the CT — each of whom owes the patient a separate, legally recognized duty. The duty is not diluted by the involvement of multiple providers; it is expanded.
Breach of the Standard of Care
Breach is established through expert testimony by a board-certified physician in the defendant’s specialty who testifies that the defendant’s conduct fell below the accepted standard of care. In brain tumor cases, that standard or ‘duty of care’ is established by the expert physician’s experience, training, and knowledge. Experts may also draw upon AAN, ACEP, ACR, and NCCN guidelines and medical literature when offering their expert conclusions about the appropriate evaluation of the specific presenting symptoms and the appropriate choice of imaging modality for those symptoms.
Causation and the Lost Chance Doctrine
Causation is where brain cancer cases are most bitterly contested — particularly in GBM cases, where the defense argues that the tumor was always fatal regardless of timing. In GBM cases, the causation argument focuses on what surgical options were lost during the delay, whether the extent of resection was compromised, and whether the period of functional neurological decline was extended unnecessarily. In low-grade glioma cases, the argument may be that the tumor transformed from Grade II or III to Grade IV during the period of diagnostic failure — and that a patient who had a potentially controllable tumor now faces one that is not. In both categories, the harm is specific, measurable, and supported by the published oncology literature.
Pennsylvania courts recognize the lost chance doctrine, which permits a plaintiff to recover when a physician’s negligence materially reduced the patient’s chance of a better outcome — even if the patient’s overall prognosis was less than 50% at the time of the negligent act. The Pennsylvania Supreme Court addressed this framework in Hamil v. Bashline and its progeny. An expert neurooncologist testifies to what the tumor’s grade, location, and resectability were at the time diagnosis should have been made — and what they were at the time it actually was — and quantifies the harm caused during the period of delay.
Damages
Damages in brain cancer malpractice cases include the additional suffering associated with a more advanced presentation, the loss of surgical options, more aggressive and debilitating treatment, accelerated cognitive and physical decline, and shortened life. Where the patient has died, both wrongful death and survival action claims are available under Pennsylvania law.
Â
What Is a Brain Cancer Misdiagnosis Case Worth in Pennsylvania?
Economic Damages
Economic damages are the objectively quantifiable financial losses caused by the delay. They include past and future medical expenses (neurosurgery, radiation, chemotherapy, immunotherapy, rehabilitation, long-term personal care); lost wages and the total loss of future earning capacity for a patient whose cognitive or physical function is compromised by advanced disease; and projected lifetime costs of care developed with a certified life-care planner. Brain cancer cases involving patients in the prime of their working lives — with significant earning capacity and dependent families — can generate economic damages that reach well into the millions.
Non-Economic Damages
Non-economic damages include physical pain and suffering; the cognitive and psychological anguish of facing a terminal diagnosis when earlier diagnosis might have changed the trajectory; the loss of the ability to work, provide care and guidance to children, pursue meaningful activities, and be present in the lives of loved ones; and loss of consortium. These damages are presented through testimony from the patient, the patient’s family and friends, treating physicians or therapists and medical or psychiatric experts.
Pennsylvania Has No Cap on Malpractice Damages
Pennsylvania does not impose a statutory ceiling on compensatory damages — economic or non-economic — in medical malpractice cases. Under Article III, Section 18 of the Pennsylvania Constitution, the General Assembly is prohibited from limiting the amount a plaintiff may recover for personal injuries. This constitutional protection means that no jury award for compensatory damages in a Pennsylvania malpractice case can be reduced by statute. Punitive damages, awarded only in rare cases involving particularly egregious conduct, are separately limited to twice the amount of compensatory damages for individual physicians unless the conduct was intentional. Claims against government-affiliated entities face different and more restrictive caps — but private hospitals and physicians, who are the defendants in the vast majority of brain cancer delay cases, are not subject to any compensatory cap. Brain cancer cases involving working-age patients with dependent families, significant earning capacity, and catastrophic care needs can generate awards that fully reflect the magnitude of what was lost.
Â
Pennsylvania Law: Filing a Brain Cancer Malpractice Claim
The Certificate of Merit: Pa.R.C.P. No. 1042.3
Under the Pennsylvania MCARE Act, a Certificate of Merit must be filed within 60 days of filing a medical malpractice complaint. It must be signed by a board-certified physician in the same or a related specialty as the defendant, attesting that there is a reasonable probability that the care deviated from accepted professional standards and caused the claimed harm. At Lupetin & Unatin, we retain qualified experts — including neuroradiologists, neurologists, neurooncologists, and neurosurgeons — before the complaint is filed, ensuring this requirement is met without exception.
The Two-Year Statute of Limitations and the Discovery Rule
Pennsylvania’s statute of limitations for medical malpractice claims is two years under 42 Pa. C.S.A. § 5524(2). The two-year period generally begins on the date of the negligent act. Under the discovery rule, recognized in Pennsylvania through established case law, the limitations period does not begin to run until the plaintiff knew, or through the exercise of reasonable diligence should have known, that they were harmed by a medical error. Importantly, the Pennsylvania Supreme Court struck down the MCARE Act’s seven-year statute of repose as unconstitutional in Yanakos v. UPMC, 218 A.3d 1214 (Pa. 2019), under the Open Courts provision of the Pennsylvania Constitution. There is therefore no absolute outer time limit on the discovery rule in Pennsylvania medical malpractice cases. A patient who was told repeatedly that their symptoms were benign may not reasonably connect a later brain cancer diagnosis to prior negligent care until they review their records with an attorney — and the discovery rule preserves that claim. Even so, evidence degrades and witnesses become unavailable over time, and we strongly encourage early consultation.
Tolling for Minors
When the patient is a minor — as in pediatric brain tumor cases involving medulloblastoma, low-grade glioma, or ependymoma — the statute of limitations does not begin to run until the patient reaches age 18, meaning a claim must be filed before their 20th birthday. Parents of children whose brain cancer was delayed in diagnosis should consult an attorney as early as possible; waiting allows evidence to degrade and witnesses to become unavailable.
Hospital Liability and Physician Liability
Both the treating physician and the institution are frequently defendants in brain cancer delay cases. Hospitals may be held directly liable under the corporate negligence doctrine recognized in Thompson v. Nason Hospital — where systemic failures (inadequate critical-result communication protocols, failure to maintain systems ensuring that incidental imaging findings are followed up, understaffing of neurology services) contributed to the delay.
Frequently Asked Questions
Not necessarily. The key legal question is not whether GBM is universally fatal — it is whether the delay materially reduced the patient’s chance of a longer or better survival, or caused harm beyond what would have existed with timely diagnosis. Many GBM cases involve patients whose tumors were smaller, lower-grade, or confined at the point when diagnosis should have been made. A neurooncologist can often testify that earlier diagnosis would have provided a greater chance of gross total surgical resection, a longer window of functional life, or access to clinical trials for which the patient no longer qualified by the time of late diagnosis. And if the tumor was not GBM when it should have been caught — if it was a Grade II or III glioma that transformed during the period of negligent delay — that transformation itself is compensable harm, regardless of the ultimate prognosis.
A normal non-contrast CT does not exclude a brain tumor. Many brain tumors — particularly low-grade gliomas and small metastases — are invisible on non-contrast CT. If your symptoms warranted brain MRI under published clinical guidelines (first adult seizure, progressive headache with focal neurological findings, new cognitive or personality change) and the emergency physician ordered CT instead, the normal CT result does not close the case — it may be part of it. The question is whether the physician chose the wrong test for the clinical situation, and whether the wrong test missed the tumor that was there.
This is a common defense argument, and it requires scrutiny. Tumor size alone does not determine whether delay caused compensable harm. Location matters (small tumors in eloquent cortex cause significant deficits even at small size). Grade transformation matters (a tumor that was WHO Grade II when it should have been caught and became Grade IV during the delay has caused irreversible harm regardless of size). Surgical resectability matters (a tumor that became inaccessible during the delay cost the patient the option of maximal safe resection). A neurooncologist can address all these dimensions in testimony that the defense’s size argument does not anticipate.
A hereditary predisposition does not eliminate negligence — it heightens the physician’s duty. When a patient has a documented hereditary syndrome associated with elevated brain tumor risk, the standard of care requires a lower threshold for investigation when symptoms arise. A physician who knows the patient has NF1 or Li-Fraumeni syndrome and responds to new headaches with ibuprofen and stress management has failed to apply the heightened vigilance that the patient’s diagnosis required.
Yes. Radiologists who fail to identify a brain mass on imaging they were specifically asked to interpret, who assign a benign label to an indeterminate enhancing lesion without recommending follow-up, or who fail to communicate a critical finding to the ordering physician can be held liable for malpractice. Because imaging is preserved digitally, this evidence does not degrade — it is available years after the original interpretation, and an independent neuroradiologist can review the original images and testify about what was present and visible at the time.
The general statute of limitations is two years from the date of the negligent act, or from the date you knew or reasonably should have known that a medical error caused your harm. For minors, the clock does not start until age 18. Because evidence degrades and witness memories fade, we strongly encourage families to contact us as soon as they suspect negligence — not when the two-year window is nearly closed.
Nothing unless we recover compensation for you. Lupetin & Unatin handles every brain cancer misdiagnosis case on a contingency fee basis. There is no retainer, no hourly charge, and no out-of-pocket cost for the investigation. We advance all costs — expert fees, medical record retrieval, deposition expenses — and recover them only from the proceeds of any settlement or verdict.
Yes. Pennsylvania law provides two separate avenues of recovery. A wrongful death claim compensates the family for their losses — funeral expenses, loss of income, loss of companionship and guidance. A survival action preserves the claims the patient themselves would have had — for their own pain, suffering, and economic losses before death. Both may be brought together, and in cases involving young patients with dependent families, the combined value can be substantial.
Why Lupetin & Unatin Investigates Brain Cancer Misdiagnosis Cases
Brain cancer delay cases are among the most technically demanding medical malpractice investigations we undertake. The evidentiary record spans multiple specialties — primary care, emergency medicine, neurology, neuroradiology, neurosurgery, and neuropathology — and the standard-of-care analysis for each provider requires a separate qualified expert. We do not approach these cases as generic delayed-diagnosis claims. We obtain the complete electronic medical record and if necessary, its underlying audit log. We retrieve every imaging study — including the original DICOM files, not merely the written reports — and have them independently reviewed by a neuroradiologist who can testify to what was visible on that scan at the time it was read, and what the standard of care required the radiologist to say about it. Where necessary, we obtain the original pathology specimen and have it reviewed for both histological classification and required molecular markers. And we work with oncologists to reconstruct, precisely and specifically, what the patient’s tumor grade, surgical options, and survival probability looked like at the time diagnosis should have been made — versus what they looked like when it was actually made. That reconstruction is the foundation of the causation argument. In Pennsylvania, it is what turns a sympathetic case into a winnable one.
What to Expect When You Contact Lupetin & Unatin
We understand that calling a medical malpractice attorney while you or someone you love is still facing the reality of a brain cancer diagnosis is not easy. Here is exactly what will happen:
- We will ask you to walk us through the timeline: when symptoms started, what physicians you saw, what you were told, when the brain cancer was eventually diagnosed, and what your treating team has said about the current status. This helps us assess whether the statute of limitations is at risk and where the investigation should begin.
- With your authorization, we retrieve your complete medical records from every provider involved — including imaging studies in their original digital format, radiology reports, pathology reports, and the electronic medical record audit log showing who accessed your chart, when, and what they reviewed. You do not have to contact the hospital or any physician’s office yourself.
- Our team, working with external experts in neurology, neuroradiology, neurooncology, and neuropathology, reviews those records thoroughly. This typically takes four to eight weeks. At the end of it, we give you an honest assessment: if we believe the standard of care was breached and the breach caused measurable harm, we tell you what we found and what the path forward looks like. If we do not believe a viable claim exists, we tell you that too — and we explain why.
- There is no cost and no obligation at any stage. The consultation is free. The investigation is free. If we take your case, it is on a contingency fee basis — you pay nothing unless and until we recover compensation on your behalf.
Contact Lupetin & Unatin for a Confidential Case Review
If you or someone you love received a brain cancer diagnosis after months or years of symptoms that were dismissed, misattributed, or never properly investigated — or after imaging was ordered that should have detected the tumor and did not — the most important step you can take right now is to find out whether those months mattered, and whether someone is accountable for them.
The lawyers of Lupetin & Unatin do not make that determination by guessing. We make it by reviewing records, obtaining independent expert analysis, and applying the same analytical rigor to every case that we apply in the courtroom. If the evidence shows negligence, we pursue it. If it does not, we tell you honestly.
Call Lupetin & Unatin in Pittsburgh, Pennsylvania at 412-281-4100 for a confidential, no-cost review of your case. There is no pressure, no commitment, and no cost to speak with us. We are located in the Grant Building in downtown Pittsburgh and represent clients throughout Pennsylvania.
Free Consultation — No Fee Unless We Win
Call Lupetin & Unatin in Pittsburgh, Pennsylvania at 412-281-4100 for a confidential, no-cost review of your case. There is no pressure, no commitment, and no cost to speak with us. We are located in the Grant Building in downtown Pittsburgh and represent clients throughout Pennsylvania.